Beyond the Screen Episode 14: TeraRecon’s AI-based solutions available for the assessment of COVID-19

Welcome to the 14^th episode of Beyond the Screen, a podcast that aims to spark discussion about cutting-edge and innovative technologies in the advanced visualization and artificial intelligence space. TeraRecon has been making waves in the industry these past couple months. Most recently, we took on a brand refresh with a new logo, color scheme, and website. We also introduced our parent company, SymphonyAI's Eureka Brand to our AI products, now known as the Eureka Clinical AI Platform and the Eureka AI Results Explorer. This has been a mammoth project and we are so proud to finally share it with you.

TeraRecon would like to send out a heartfelt thank you to all the healthcare professionals and members around the world who are working tirelessly to help their patients and communities during the COVID-19 pandemic.

While the pandemic has been affecting everyone around the globe, our customers have asked us to help them better assess and care for patients. In this week’s episode, we will focus on these new tools that have been developed to help aid in the clinical assessment of COVID-19 and tracking of the disease progression. Rebecca McDade, TeraRecon’s Senior Director of Clinical Support will walk us through Intuition’s Lung Density Analysis II Workflow* and our Emergency AI Lung Suite* available for not only COVID-19 diagnosis but various diseases of the lung. Tune in as we discover the key features our workflows bring to our front-line healthcare workers.

In this week’s episode, you will learn about:

• TeraRecon’s FDA cleared, Lung Density Analysis II workflow and the unique tools enhanced segmentation engine specifically designed to include high-density areas of the lung.
• The Emergency Lung AI Suite, which allows for rapid lung analysis, the ability to edit those results, and then easily share.
• Updates in our latest Intuition 4.4.13 P6 software release.
• The emerging stroke conditions in COVID-19 and the tools we have in place and are developing to help clinical diagnosis and tracking of brain conditions.
• Our approach to AI and goal of allowing the physician to interact with AI results thus making their lives faster, easier, and better.

As this pandemic continues to develop, there are certainly more long-term symptoms that we will be watching for. Stroke is only the latest in a long string of new information. As we monitor the world's health, we'll continue to work to provide the tools necessary for clinicians to quickly and effectively diagnose patients.

TeraRecon has always been an industry standard name, and as we move into this new era where things seem uncertain, you can count on TeraRecon to continue to innovate ahead of market demand and develop the tools that save lives.

Have a question about today’s episode or want to join the discussion about cutting-edge and innovative technologies in the advanced visualization space? Email us at info@terarecon.com.

Listen and subscribe to our podcast from your mobile device:
Via Apple Podcasts | Via Google Play | Via Spotify

Resources:

• Adoption of SymphonyAI’s Eureka Brand
• Eureka Clinical AI Platform
• Eureka AI Results Explorer
• The Latest Intuition P6 Updates

This podcast is brought to you by TeraRecon, the leader in advanced visualization, image sharing, post-processing, and artificial intelligence solutions.

*The following are important statements regarding the use of TeraRecon’s Lung Density Analysis II and Emergency Lung AI Suite offerings:

• Volumetric histogram and lung segmentation functionality are FDA cleared features of Intuition. This functionality is not FDA cleared specifically for COVID-19. It must only be used as an aid and that final interpretation should be performed by a licensed healthcare practitioner with the appropriate training.
• The results should not be used for screening and the software does not provide specific disease detection and should not be solely or primarily relied upon to diagnose or treat COVID-19.
• This device is not indicated for the diagnosis of COVID-19 and that in vitro diagnostic testing is currently the only definitive method to diagnose COVID-19.
• This tool is available by specific licenses only.
• The default thresholds are generalized recommendations and are user adjustable. The image analysis should only be used as an aid and the final interpretation should be performed by a licensed healthcare practitioner with the appropriate training.
• Under the current circumstances, the COVID-19 functionality is cleared for diagnostic use in the US only.

The following is an important statement regarding TeraRecon's Eureka NeuroAI Suite

• Eureka NeuroAI is pending 510k clearance and is currently not for diagnostic use.